NEWS
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to illustrate the antibody's capacity to inhibit both pathways in a single therapy, potentially broadening its clinical applications across various autoimmune diseases. Zura Bio also disclosed timelines for Phase 2 trials: systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
955Followers
63Following
6457Visitors
Follow